A Double-blind, Placebo-controlled, Randomized, 3-period, 3-treatment Crossover Study to Evaluate the Effect of Multiple Oral Dose Administration of SEP-363856 in Male and Female Adult Subjects With Narcolepsy-cataplexy
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Ulotaront (Primary)
- Indications Cataplexy; Narcolepsy
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization; Sunovion Pharmaceuticals
- 24 Aug 2021 New trial record